+検索条件
-Structure paper
タイトル | Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. |
---|---|
ジャーナル・号・ページ | Sci Transl Med, Vol. 14, Issue 646, Page eabn1252, Year 2022 |
掲載日 | 2022年5月25日 |
著者 | Andrew C Hunt / James Brett Case / Young-Jun Park / Longxing Cao / Kejia Wu / Alexandra C Walls / Zhuoming Liu / John E Bowen / Hsien-Wei Yeh / Shally Saini / Louisa Helms / Yan Ting Zhao / Tien-Ying Hsiang / Tyler N Starr / Inna Goreshnik / Lisa Kozodoy / Lauren Carter / Rashmi Ravichandran / Lydia B Green / Wadim L Matochko / Christy A Thomson / Bastian Vögeli / Antje Krüger / Laura A VanBlargan / Rita E Chen / Baoling Ying / Adam L Bailey / Natasha M Kafai / Scott E Boyken / Ajasja Ljubetič / Natasha Edman / George Ueda / Cameron M Chow / Max Johnson / Amin Addetia / Mary-Jane Navarro / Nuttada Panpradist / Michael Gale / Benjamin S Freedman / Jesse D Bloom / Hannele Ruohola-Baker / Sean P J Whelan / Lance Stewart / Michael S Diamond / David Veesler / Michael C Jewett / David Baker / |
PubMed 要旨 | New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a cell-free expression ...New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a cell-free expression workflow to rapidly screen and optimize constructs containing multiple computationally designed miniprotein inhibitors of SARS-CoV-2. We found the broadest efficacy was achieved with a homotrimeric version of the 75-residue angiotensin-converting enzyme 2 (ACE2) mimic AHB2 (TRI2-2) designed to geometrically match the trimeric spike architecture. Consistent with the design model, in the cryo-electron microscopy structure TRI2-2 forms a tripod at the apex of the spike protein that engaged all three receptor binding domains simultaneously. TRI2-2 neutralized Omicron (B.1.1.529), Delta (B.1.617.2), and all other variants tested with greater potency than the monoclonal antibodies used clinically for the treatment of COVID-19. TRI2-2 also conferred prophylactic and therapeutic protection against SARS-CoV-2 challenge when administered intranasally in mice. Designed miniprotein receptor mimics geometrically arrayed to match pathogen receptor binding sites could be a widely applicable antiviral therapeutic strategy with advantages over antibodies in greater resistance to viral escape and antigenic drift, and advantages over native receptor traps in lower chances of autoimmune responses. |
リンク | Sci Transl Med / PubMed:35412328 / PubMed Central |
手法 | EM (単粒子) |
解像度 | 3.0 - 5.2 Å |
構造データ | EMDB-26507: SARS-CoV-2 spike in complex with Multivalent miniprotein inhibitor FUS231-P24 (2RBDs open) EMDB-26508: SARS-CoV-2 spike in complex with multivalent miniprotein inhibitor FUS231-P24 (3RBDs open) EMDB-26509: SARS-CoV-2 spike in complex with multivalent miniprotein inhibitor FUS31-G10 (2RBDs open) EMDB-26510: SARS-CoV-2 spike in complex with multivalent miniprotein inhibitor FUS31-G10 (3RBDs open) EMDB-26511, PDB-7uhb: EMDB-26512, PDB-7uhc: |
化合物 | ChemComp-NAG: |
由来 |
|
キーワード | VIRAL PROTEIN / SARS-CoV-2 / COVID-19 / spike glycoprotein / fusion protein / neutralizing antibodies / Structural Genomics / Seattle Structural Genomics Center for Infectious Disease / SSGCID / Inhibitor / miniprotein inhibitor |